<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289649</url>
  </required_header>
  <id_info>
    <org_study_id>K-924-02</org_study_id>
    <nct_id>NCT04289649</nct_id>
  </id_info>
  <brief_title>K-924 Phase III Confirmatory Study</brief_title>
  <official_title>A Phase III, Multicenter, Randomized, Clinial Trial to Evaluate the Efficacy and Safety of K-924 in Patienta With Hypercholesterolemia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, active-controlled, randomized, double-blind comparative study to compare the&#xD;
      efficacy and safety of K-924 LD tablet or K-924 HD tablet to pitavastatin 2 mg or 4 mg in&#xD;
      patienta with hypercholesterolemia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Actual">November 21, 2020</completion_date>
  <primary_completion_date type="Actual">November 21, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy : % change from baseline in LDL-C (Friedewald formula) (mg / dL)</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in LDL-C (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in non-HDL-C (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in HDL-C (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in Total Cholesterol (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : % change or change from baseline in TG (mg / dL)</measure>
    <time_frame>From baseline upto week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">293</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>K-924 LD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-924 LD tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K-924 HD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-924 HD tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin 2 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>K-924 LD Placebo tablet once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pitavastatin 4 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>K-924 HD Placebo tablet once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-924 LD</intervention_name>
    <description>Pitavastatin 2 mg / Ezetimibe 10 mg tables</description>
    <arm_group_label>K-924 LD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-924 HD</intervention_name>
    <description>Pitavastatin 4 mg / Ezetimibe 10 mg tables</description>
    <arm_group_label>K-924 HD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-924 LD Placebo</intervention_name>
    <description>Pitavastain 2 mg</description>
    <arm_group_label>Pitavastatin 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-924 HD Placebo</intervention_name>
    <description>Pitavastain 4 mg</description>
    <arm_group_label>Pitavastatin 4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with hypercholesterolemia had to be age 20 years or older at written informed&#xD;
             consent (ICF)&#xD;
&#xD;
          2. Patients who have been on a diet and / or exercise regimen more than 12 weeks before&#xD;
             the screening&#xD;
&#xD;
          3. Those whose LDL-C (Friedewald formula) at the screening any of the following in the&#xD;
             category classification based on Japan Atherosclerosis Society guidelines for&#xD;
             prevention Atherosclerotic Cardiovascular Disease 2017&#xD;
&#xD;
               -  Low risk of primary prevention : LDL-C =&gt; 160 mg/dL&#xD;
&#xD;
               -  Medium risk of primary prevention : LDL-C =&gt; 140 mg/dL&#xD;
&#xD;
               -  High risk of primary prevention : LDL-C =&gt; 120 mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a history of myopathy or rhabdomyolysis due to pitavastatin or ezetimibe&#xD;
&#xD;
          2. Patients with a history of hypersensitivity due to pitavastatin or ezetimibe&#xD;
&#xD;
          3. Patients with severe liver damage (Child Pugh Class B or higher) or biliary&#xD;
             obstruction&#xD;
&#xD;
          4. Pregnant women, lactating women, women planning to become pregnant or lactating during&#xD;
             the study period, or pregnant women who do not use specific contraceptive methods&#xD;
&#xD;
          5. Patients whose CK is 3 times or more of the upper limit of the reference value at&#xD;
             screening&#xD;
&#xD;
          6. Patients whose AST and ALT is 2 times or more of the upper limit of the reference&#xD;
             value at screening&#xD;
&#xD;
          7. Patients wiht type 1 diabetes or uncontrolled type 2 diabetes as defined HbA1c 8% or&#xD;
             more at screening&#xD;
&#xD;
          8. Patients with uncontrolled hypertension as defined systolic blood pressure of 160 mmHg&#xD;
             or more or diastolic blood pressure of 100 mmHg or more at screening&#xD;
&#xD;
          9. Patients with eGFR of less than 30 mL / min / 1.73 mÂ² at screening or dialysis&#xD;
&#xD;
         10. Patients with heart failure class III or higher according to NYHA cardiac function&#xD;
             classification&#xD;
&#xD;
         11. Patients with uncontrolled arrhythmia&#xD;
&#xD;
         12. Patients with uncontrolled metabolic endocrine disease&#xD;
&#xD;
         13. Patients with a history of coronary artery disease or patient with familial&#xD;
             hypercholesterolemia&#xD;
&#xD;
         14. Patients with malignant tumors or who are judged to have a high possibility of relapse&#xD;
&#xD;
         15. Patients who have collected 200 mL or more within 4 weeks before screening, 400 mL or&#xD;
             more of blood within 12 weeks for males or 16 weeks for females, or within 2 weeks for&#xD;
             (Plasma component / platelet component)&#xD;
&#xD;
         16. Persons with a history of severe drug allergy (anaphylactic shock, etc.)&#xD;
&#xD;
         17. Patients who need contraindicated drugs during the study period after obtaining&#xD;
             consent&#xD;
&#xD;
         18. Patients with TG of 400 mg / dL or more at screening&#xD;
&#xD;
         19. Patients who have LDL apheresis&#xD;
&#xD;
         20. Patients with malabsorption or history, or who have undergone gastrointestinal surgery&#xD;
             (excluding appendectomy, hernia treatment, etc.) that may affect absorption.&#xD;
&#xD;
         21. Patients with Alcohol or drug addiction&#xD;
&#xD;
         22. Patients who participate in other clinical trials within 16 weeks prior to study drug&#xD;
             administration and who are administered non-placebo investigational drugs, or who&#xD;
             participate in other clinical trials concurrently with this study&#xD;
&#xD;
         23. Patients who have received K-924&#xD;
&#xD;
         24. Patients who judged to be inappropriate by the Investigator or Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OCROM Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai OPHAC Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Heishinkai ToCROM Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>December 22, 2020</last_update_submitted>
  <last_update_submitted_qc>December 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

